Recombinant CD22 (Epratuzumab Biosimilar) 抗体
This anti-CD22 (Epratuzumab Biosimilar) antibody is a Human 单克隆 antibody detecting CD22 (Epratuzumab Biosimilar) in BP, FACS 和 IP. Suitable for 人, Cynomolgus 和 猕猴.
Quick Overview for Recombinant CD22 (Epratuzumab Biosimilar) 抗体 (ABIN5668216)
抗原
CD22 (Epratuzumab Biosimilar)
抗体类型
Recombinant Antibody
适用
人, Cynomolgus, 猕猴
宿主
Human
克隆类型
单克隆
标记
This CD22 (Epratuzumab Biosimilar) antibody is un-conjugated
应用范围
Blocking Peptide (BP), Flow Cytometry (FACS), Immunoprecipitation (IP)
克隆位点
HL22
-
-
原理
- Anti-CD22 [hL22 (Epratuzumab)], Human IgG1, kappa
-
特异性
- This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.
-
交叉反应
- Cynomolgus, 猕猴
-
产品特性
-
Original Species of Ab: Human
Original Format of Ab: IgG1
-
纯化方法
- Protein A affinity purified
-
纯度
- > 98 % as determined by SDS-PAGE
-
内毒素水平
- Endotoxin is < 1.0 EU/mg as determined by the LAL method
-
免疫原
- This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).
-
亚型
- IgG1 kappa
-
-
anti-CD22 (Epratuzumab Biosimilar) antibody
适用: 人, Cynomolgus, 猕猴 BP, FACS, IP 宿主: 兔 Chimeric hL22 unconjugated Recombinant Antibody
-
-
应用备注
- Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010).
-
限制
- 仅限研究用
-
-
-
浓度
- 1 mg/mL
-
缓冲液
- PBS with 0.02 % Proclin 300.
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
-
- CD22 (Epratuzumab Biosimilar)
-
物质类
- Biosimilar
-
背景
- Leu14, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14
-
UniProt
- P20273
抗原
-
You are here:
